FANCG (Fanconi anemia, complementation group G)

2002-06-01   Jean-Loup Huret  

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Identity

HGNC
LOCATION
9p13.3
IMAGE
Atlas Image
LEGEND
Probe(s) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics
LOCUSID
ALIAS
FAG,XRCC9
FUSION GENES

DNA/RNA

Description

14 exons; 1869 bp open reading frame

Transcription

2.2 and 2.5 kb

Proteins

Description

622 amino acids, 69 kDa; contains a leucine zipper; can be phosphorylated

Expression

weak; testis, thymus, lymphoblasts.

Localisation

predominantly nuclear

Function

part of the FA complex with FANCA, FANCC, FANCE, and FANCF; this complex is only found in the nucleus.
  • FANCA and FANCG form a complex in the cytoplasm, through a N-term FANCA (involving the nuclear localization signal) - FANCG interaction; FANCC join the complex; phosphorylation of FANCA would induce its translocation into the nucleus.This FA complex translocates into the nucleus, where FANCE and FANCF are present; FANCE and FANCF join the complex. The FA complex subsequently interacts with FANCD2 by monoubiquitination of FANCD2 during S phase or following DNA damage. Activated (ubiquinated ) FANCD2, downstream in the FA pathway, will then interact with other proteins involved in DNA repair, possibly BRCA1; after DNA repair, FANCD2 return to the non-ubiquinated form.
  • Homology

    no known homology

    Mutations

    Germinal

    wide range of mutations (splice, nonsense, missense)

    Implicated in

    Entity name
    Fanconi anaemia (FA); FANCG is implicated in the FA complementation group G; it represents about 10% of FA cases.
    Disease
    Fanconi anaemia is a chromosome instability syndrome/cancer prone disease (at risk of leukaemia and squamous cell carcinoma)
    Prognosis
  • Fanconi anaemias prognosis is poor; mean survival is 20 years: patients die of bone marrow failure (infections, haemorrhages), leukaemia, or solid cancer.
  • It has recently been shown that significant phenotypic differences were found between the various complementation groups. FA group G patients had more severe cytopenia and a higher incidence of leukemia. FA group G patients patients are high-risk groups with a poor hematologic outcome and should be considered as candidates both for frequent monitoring and early therapeutic intervention.
  • Cytogenetics
    Spontaneously enhanced chromatid-type aberrations (breaks, gaps, interchanges; increased rate of breaks compared to control, when induced by specific clastogens known as DNA cross-linking agents (e.g. mitomycin C, diepoxybutane).

    Bibliography

    Pubmed IDLast YearTitleAuthors

    Other Information

    Locus ID:

    NCBI: 2189
    MIM: 602956
    HGNC: 3588
    Ensembl: ENSG00000221829

    Variants:

    dbSNP: 2189
    ClinVar: 2189
    TCGA: ENSG00000221829
    COSMIC: FANCG

    RNA/Proteins

    Gene IDTranscript IDUniprot
    ENSG00000221829ENST00000378643O15287
    ENSG00000221829ENST00000378643Q53XM5
    ENSG00000221829ENST00000425676F8WC08
    ENSG00000221829ENST00000448890C9JSE3

    Expression (GTEx)

    0
    5
    10
    15
    20
    25
    30
    35

    Pathways

    PathwaySourceExternal ID
    Fanconi anemia pathwayKEGGko03460
    Fanconi anemia pathwayKEGGhsa03460
    FA core complexKEGGhsa_M00413
    FA core complexKEGGM00413
    DNA RepairREACTOMER-HSA-73894
    Fanconi Anemia PathwayREACTOMER-HSA-6783310

    Protein levels (Protein atlas)

    Not detected
    Low
    Medium
    High

    References

    Pubmed IDYearTitleCitations
    348640952022In silico study of missense variants of FANCA, FANCC and FANCG genes reveals high risk deleterious alleles predisposing to Fanconi anemia pathogenesis.1
    348640952022In silico study of missense variants of FANCA, FANCC and FANCG genes reveals high risk deleterious alleles predisposing to Fanconi anemia pathogenesis.1
    329475772021Clinical and Genetic Features of Patients With Fanconi Anemia in Lebanon and Report on Novel Mutations in the FANCA and FANCG Genes.1
    333942272021Severe telomere shortening in Fanconi anemia complementation group L.3
    344365272021Frequent internuclear bridging in a Fanconi anemia patient with FANCG mutation.0
    329475772021Clinical and Genetic Features of Patients With Fanconi Anemia in Lebanon and Report on Novel Mutations in the FANCA and FANCG Genes.1
    333942272021Severe telomere shortening in Fanconi anemia complementation group L.3
    344365272021Frequent internuclear bridging in a Fanconi anemia patient with FANCG mutation.0
    325297602020Endocrine profiling in patients with Fanconi anemia, homozygous for a FANCG founder mutation.4
    329890152020Loss of Mitochondrial Localization of Human FANCG Causes Defective FANCJ Helicase.2
    325297602020Endocrine profiling in patients with Fanconi anemia, homozygous for a FANCG founder mutation.4
    329890152020Loss of Mitochondrial Localization of Human FANCG Causes Defective FANCJ Helicase.2
    298438522018Fanconi anaemia in South Africa: Past, present and future.2
    300571982018FANCA Promotes DNA Double-Strand Break Repair by Catalyzing Single-Strand Annealing and Strand Exchange.48
    298438522018Fanconi anaemia in South Africa: Past, present and future.2

    Citation

    Jean-Loup Huret

    FANCG (Fanconi anemia, complementation group G)

    Atlas Genet Cytogenet Oncol Haematol. 2002-06-01

    Online version: http://atlasgeneticsoncology.org/gene/295/deep-insight-explorer/teaching-explorer/favicon/favicon-32x32.png